The synergic effect of chemotherapy (azacytidine) and IDH inhibitors (ivosidenib) was evaluated in IDH1mut AML patients, and this combination is now approved by the FDA for patients not eligible for intensive induction chemotherapy; a similar therapeutic strategy could be further evaluated in IDHmut gliomas [61]. Here, IDH2 is linked to acute myeloid leukemia.